Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
JAMA Ophthalmology|October 27, 2015
A Region-of-Interest Approach for Detecting Progression of Glaucomatous Damage With Optical Coherence TomographyDonald C Hood, Daiyan Xin, Diane Wang, et al.
Orbit (Amsterdam, Netherlands)|February 28, 2022
Intravascular Large B-cell Lymphoma Diagnosed by Nasal Biopsy in a Patient Presenting with Bilateral Ptosis and OphthalmoplegiaDiane Wang, Charlotte L Marous, Fatih Ozay, et al.
The Oncologist|June 28, 2017
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 ResultsSibylle Loibl, Nicholas C Turner, Jungsil Ro, et al.
Molecular Cancer Therapeutics|July 9, 2008
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorAndrea J Gonzales, Kenneth E Hook, Irene W Althaus, et al.
Journal of Neuro-Oncology|December 25, 2019
DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapyYoshie Umemura, Diane Wang, Kyung K Peck, et al.
American Journal of Respiratory Cell and Molecular Biology|February 18, 2010
Involvement of Gax gene in hypoxia-induced pulmonary hypertension, proliferation, and apoptosis of arterial smooth muscle cellsShijin Xia, Xiantao Tai, Yaoli Wang, et al.
Oral Oncology|February 11, 2021
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trialDouglas R Adkins, Jin-Ching Lin, Assuntina Sacco, et al.
Targeted Oncology|February 25, 2025
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple MyelomaMohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, et al.
Cancer Research Communications|March 27, 2023
A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the PancreasManuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim, et al.
Cancer Chemotherapy and Pharmacology|February 21, 2013
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiationRuth Plummer, Paul Lorigan, Neil Steven, et al.
Pageof 15